Investing.com -- 在美国食品药品监督管理局(FDA)解除了对其已完成的评估zetomipzomib治疗自身免疫性肝炎(AIH)患者的2a期临床试验的部分暂停令后,Kezar Life Sciences Inc (NASDAQ:KZR)股价上涨4%。 这家临床阶段生物技术公司宣布,FDA的肝脏病学和营养部门在对zetomipzomib项目进行全面安全评估后解除了暂停令。这一进展使...
Source LinkInvesting.com -- 在美国食品药品监督管理局(FDA)解除了对其已完成的评估zetomipzomib治疗自身免疫性肝炎(AIH)患者的2a期临床试验的部分暂停令后,Kezar Life Sciences Inc (NASDAQ:KZR)股价上涨4%。 这家临床阶段生物技术公司宣布,FDA的肝脏病学和营养部门在对zetomipzomib项目进行全面安全评估后解除了暂停令。这一进展使...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.